Drugs / INCB062079
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03144661 | May 2017 → Jun 2020 | cholangiocarcinoma, esophageal cancer, hepatocellular carcinoma, nasopharyngeal carcinoma +1 | Incyte Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB062079 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03144661 ↗ |
| Action | Inhibit | “INCB062079, an oral, selective, FGFR4 inhibitor, inhibits growth in FGF19/FGFR4-driven liver cancer models.” PMID 36787089 ↗ Feb 2023 |
| Route | Oral | “an oral, selective, FGFR4 inhibitor” PMID 36787089 ↗ Feb 2023 |
| Target | FGFR4 | “INCB062079, an oral, selective, FGFR4 inhibitor” PMID 36787089 ↗ Feb 2023 |